TI
ENGN icon

Trexquant Investment’s enGene Therapeutics ENGN Stock Holding History

Trexquant Investment’s Portfolio ENGN Stock Details ENGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-104,697
Closed -$713K – 1978
2026
Q1 		$713K Buy
+104,697
New +$932K 0.01% 1343

Other funds holding ENGN

FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return

Trexquant Investment's ENGN Position: Q2 2026 in Review

Trexquant Investment sold out of enGene Therapeutics (ENGN) in Q2 2026, closing a stake of 104,697 shares — an estimated $713K sold.

Trexquant Investment first reported a position in ENGN in Q1 2026 and held it in 1 quarter. The position peaked at $713K in Q1 2026. 60 funds tracked by Wall St. Rank hold ENGN as of Q2 2026.

  • Trexquant Investment reported no remaining enGene Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Trexquant Investment sold 104,697 enGene Therapeutics shares in Q2 2026, an estimated $713K.
  • Trexquant Investment first reported a position in enGene Therapeutics in Q1 2026 and held it in 1 quarter.
  • Trexquant Investment's enGene Therapeutics position peaked at $713K in Q1 2026.
  • 60 funds tracked by Wall St. Rank held enGene Therapeutics as of Q2 2026.

Based on Trexquant Investment's 13F filing for Q2 2026, filed 14 Aug 2026.